News und Analysen

Over the course of the past few years, growth stocks have led the charge for the stock market. However, every year presents different challenges, and I think a different set of stocks -- a few that

Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red. They're

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in

One day after unveiling quarterly results that disappointed the market and engendered a stock sell-off, Zoetis (NYSE: ZTS) shares again tumbled. As of late-session trading on Friday, they were down

In today's video, I discuss Advanced Micro Devices (NASDAQ: AMD) and recent updates to its AI road map. To learn more, check out the short video, consider subscribing, and click the special offer

In today's video, I discuss Advanced Micro Devices (NASDAQ: AMD), its business strategy, growth opportunities, potential risks, and why artificial intelligence stock investors should not ignore this

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare stocks as a group are barely in positive territory.

However, I remain

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. And

Image source: The Motley Fool.

DexCom (NASDAQ: DXCM)Q4 2024 Earnings CallFeb 13, 2025, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue

Healthcare in vitro diagnostics company QuidelOrtho (NASDAQ: QDEL) attracted the right kind of attention from investors after posting its latest quarterly earnings report on Thursday. A rather

Shares of Zoetis (NYSE: ZTS), the leading animal pharmaceutical company, were sliding today after its 2025 guidance came up short in its fourth quarter.

Though it topped estimates on the top and

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q4 2024 Earnings CallFeb 13, 2025, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Zoetis (NYSE:ZTS), the leader in animal health solutions, released its fourth quarter results for 2024 on Feb. 13. The company reported an adjusted earnings per share (EPS) of $1.40, which exceeded

Investing in a top healthcare company whose share price has been tanking in recent years could present a huge opportunity for investors, especially when that company has been bolstering its growth

Most companies don't survive for decades, much less pay regular dividends for that long. However, some rare corporations can pull it off. These are the kinds of stocks long-term investors will often

I'm about to get a big cash infusion in my portfolio. Last year, private equity giant Blackstone agreed to buy one of my holdings, Retail Opportunity Investments Corp., in an all-cash deal. That

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q4 2024 Earnings CallFeb 12, 2025, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of BigBear.ai Holdings (NYSE: BBAI) are flying higher on Wednesday. The company's stock gained 11.6% as of 12:35 p.m. ET, but was up as much as 15.5% earlier in the day. The gain comes as the

Alkermes (NASDAQ:ALKS), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported

Cathie Wood had one of her busiest days on the trading floor in months on Tuesday. The co-founder, CEO, and ace stock picker at Ark Invest added to 17 different existing positions across her

Image source: The Motley Fool.

Exelixis (NASDAQ: EXEL)Q4 2024 Earnings CallFeb 11, 2025, 5:00 p.m. ET

Operator

Continue reading

Source Fool.com

Exelixis (NASDAQ:EXEL), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and